Glucagon Mechanism: In-depth Analysis of Its Peptide Product Composition
Abstract: Glucagon’s mechanism of action (MOA) involves G-protein-coupled receptor activation, stimulating hepatic glycogenolysis and gluconeogenesis, critical for peptide-based therapeutics. Current market trends show a 12.3% CAGR (2024–2030) driven by diabetes and congenital hyperinsulinism applications. Brand comparisons (e.g., Novo Nordisk vs. generic peptides) reveal purity differences: >99% (pharma-grade) vs. 95–98% (research-grade). Key parameters include stability (lyophilized vs. liquid), storage (-20°C vs. 2–8°C), and logistics (cold chain compliance). Regulatory certifications (FDA, GMP, ISO 13485) differentiate suppliers. Selection criteria prioritize purity, bioactivity assays, and certificate of analysis (CoA). Industry challenges include aggregation risks and short shelf-life (24 months). Future growth hinges on analog development and dual-agonist peptides.